How are RYTM strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the RYTM strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 81.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,680.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a RYTM strangle?

The breakeven for the RYTM strangle priced on this page is roughly $68.20 and $111.80 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RYTM market-implied 1-standard-deviation expected move is approximately 23.48%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current RYTM implied volatility affect this strangle?

RYTM ATM IV is at 81.90% with IV rank near 37.64%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

RYTM Strangle Strategy

RYTM (Rhythm Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

RYTM (Rhythm Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $6.42B, a beta of 1.94 versus the broader market, a 52-week range of 57.2-122.2, average daily share volume of 873K, a public-listing history dating back to 2017, approximately 283 full-time employees. These structural characteristics shape how RYTM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.94 indicates RYTM has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on RYTM?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current RYTM snapshot

As of May 15, 2026, spot at $90.66, ATM IV 81.90%, IV rank 37.64%, expected move 23.48%. The strangle on RYTM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this strangle structure on RYTM specifically: RYTM IV at 81.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 23.48% (roughly $21.29 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RYTM expiries trade a higher absolute premium for lower per-day decay. Position sizing on RYTM should anchor to the underlying notional of $90.66 per share and to the trader's directional view on RYTM stock.

RYTM strangle setup

The RYTM strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RYTM near $90.66, the first option leg uses a $95.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RYTM chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RYTM shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$95.00	$9.20
Buy 1	Put	$85.00	$7.60

RYTM strangle risk and reward

Net Premium / Debit: -$1,680.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$1,680.00
Breakeven(s): $68.20, $111.80
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

RYTM strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on RYTM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$6,819.00
$20.05	-77.9%	+$4,814.57
$40.10	-55.8%	+$2,810.14
$60.14	-33.7%	+$805.70
$80.19	-11.6%	-$1,198.73
$100.23	+10.6%	-$1,156.84
$120.28	+32.7%	+$847.59
$140.32	+54.8%	+$2,852.03
$160.36	+76.9%	+$4,856.46
$180.41	+99.0%	+$6,860.89

When traders use strangle on RYTM

Strangles on RYTM are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RYTM chain.

RYTM thesis for this strangle

The market-implied 1-standard-deviation range for RYTM extends from approximately $69.37 on the downside to $111.95 on the upside. A RYTM long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current RYTM IV rank near 37.64% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on RYTM should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RYTM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RYTM-specific events.

RYTM strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RYTM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RYTM alongside the broader basket even when RYTM-specific fundamentals are unchanged. Always rebuild the position from current RYTM chain quotes before placing a trade.

Frequently asked questions

What is a strangle on RYTM?: A strangle on RYTM is the strangle strategy applied to RYTM (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With RYTM stock trading near $90.66, the strikes shown on this page are snapped to the nearest listed RYTM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are RYTM strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the RYTM strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 81.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,680.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RYTM strangle?: The breakeven for the RYTM strangle priced on this page is roughly $68.20 and $111.80 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RYTM market-implied 1-standard-deviation expected move is approximately 23.48%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on RYTM?: Strangles on RYTM are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RYTM chain.
How does current RYTM implied volatility affect this strangle?: RYTM ATM IV is at 81.90% with IV rank near 37.64%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.